Jiangsu Wuzhong Declaration: Safeguarding the exclusive distribution rights of AestheFill, a subsidiary of the company, in mainland China.

On July 21, Suzhou Wuzhong released a solemn statement regarding the maintenance of the exclusive distribution rights of its subsidiary Datou Company's AestheFill in mainland China. Recently, the Korean subsidiary Regen Biotech, Inc. under the parent company Aimeike Technology Development Co., Ltd., sent a letter to Datou Medical Equipment Co., Ltd., intending to unilaterally terminate the exclusive distribution agreement with Datou Company for the "AestheFill" product in China. This completely deviates from the previous exclusive distribution agreement signed by both parties, the written commitment of Regen Company, and the public statements of Aimeike Company, the controlling party of Regen Company, not only constitutes a malicious trampling of the spirit of the legally binding contract, seriously undermines business ethics, but also will have a very negative impact on the order of the medical beauty market in China and globally. The company hereby solemnly declares the following facts and its position: First, Regen Company and Aimeike have maliciously breached the contract first, deviating from the principles of "gentlemen's integrity". Second, Aimeike controlling Regen Company maliciously violates the spirit of the contract, attempting to suppress competitors, with no respect for the rule of law and integrity. Third, tarnishing the good image of Chinese companies' international development, triggering a global trust crisis. Fourth, the company will use all legal means to safeguard its rights and hold Regen Company and Aimeike accountable for their legal responsibilities.